Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cleo Diagnostics Ltd

COV.AX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Healthcare Facilities & Services ·

Australia Micro Cap Analyst: N/A

Last Close

$0.21

▲ +0.00%

Market Cap $29.50M · Vol 58.78K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$29.50M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

44.83

Momentum

Beta

N/A

vs Market

52W High

$0.63

65.56% below

52W Low

$0.19

9.73% above

Volume

58.78K

Avg 134.52K

P/B

13.68

Price-to-book

ROE

N/A

Return on equity

Free Float

61.46%

Public shares

Shariah Compliance8 STANDARDS

✗ Cleo Diagnostics Ltd (COV.AX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does COV.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.35%

+1.72%

-7.81%

-52.80%

YTD

-51.24%

-22.37%

+93.23%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$1.35M
Net Income	$-4,107,438.00
Revenue Growth (YoY)	-85.59%
Gross Margin	100.00%
Operating Margin	-298.74%
Net Profit Margin	-304.51%
ROE	N/A
ROA · ROIC	-87.19% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	35.17
P/B	13.68
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	142.38M

Technical Indicators

50-Day SMA	$0.23
200-Day SMA	$0.34
RSI (14)	44.83
Beta	N/A
52-Week High	$0.63
52-Week Low	$0.19

Volume Today	58.78K
Avg Daily Volume (30D)	134.52K
Relative Volume	0.44x
Volatility (10D)	46.81
Volatility (30D)	78.67
Free Float	61.46%

Analyst Consensus

N/A

Current Price $0.21

Mean Target N/A

52W Low$0.19 52W High$0.63

Current

Target

$0.19 $0.63

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG01HBC3703

ISINAU0000288045

CountryAustralia

Sub-IndustryMedical & Diagnostic Laboratories

Earnings DateN/A

TypeStocks

Instrument TypeUNT Unit

Similar Halal Stocks

NTRA Natera, Inc. +3.31% LH Labcorp Holdings Inc. +8.78% RDNT RadNet, Inc. +0.00% LALPATHLAB.NS Dr. Lal PathLabs Ltd +1.08% NEO NeoGenomics, Inc. +4.17%

Company Profile

Cleo Diagnostics Limited is an ovarian cancer diagnostics company. Its principal activities involve the development and patent of a blood test for the detection of ovarian cancer. It focuses on bringing to market a blood test for the early diagnosis of ovarian cancer based on the novel CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is absent in non-malignant disease. It is advancing the availability of its blood test, under a modular execution strategy, which is designed to address all ovarian cancer detection markets with specific tests, including surgical triage, recurrence, high risk, and early-stage screening. Triage Test is a pre-surgical test to determine ovarian or adnexal mass for which surgical referral is required who have not yet been referred to an oncologist.